San Diego, CA, United States of America

Lin Wang

This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Halozyme, Inc., Biomarin Pharmaceutical Inc., Scripps Research Institute. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lin Wang. Retrieved from https://idiyas.com/inventor/lin-wang-kgcl9546

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2009-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Inventor Lin Wang: Revolutionizing Technology in San Diego

Introduction: Lin Wang is a visionary inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology.

Latest Patents: Lin Wang holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Lin Wang has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Lin Wang has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and knowledge-sharing to drive progress in the field of technology.

Conclusion: Lin Wang's relentless pursuit of innovation and his passion for pushing the boundaries of what is possible make him a true pioneer in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…